Phase II clinical trial of gemcitabine plus oxaliplatin in patients with metastatic pancreatic adenocarcinoma with a family history of pancreatic/breast/ovarian/prostate cancer or personal history of breast/ovarian/prostate cancer (FABRIC study)

[1]  Joon-Oh Park,et al.  Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer. , 2019, The New England journal of medicine.

[2]  M. Radovich,et al.  Germline and Somatic DNA Damage Repair Gene Mutations and Overall Survival in Metastatic Pancreatic Adenocarcinoma Patients Treated with FOLFIRINOX , 2018, Clinical Cancer Research.

[3]  Y. Okuno,et al.  Association between homologous recombination repair gene mutations and response to oxaliplatin in pancreatic cancer , 2018, Oncotarget.

[4]  Richard A. Moore,et al.  Homologous Recombination Deficiency and Platinum-Based Therapy Outcomes in Advanced Breast Cancer , 2017, Clinical Cancer Research.

[5]  Z. Szallasi,et al.  The association between germline BRCA2 variants and sensitivity to platinum‐based chemotherapy among men with metastatic prostate cancer , 2017, Cancer.

[6]  T. Kawaguchi,et al.  Familial pancreatic cancer: Concept, management and issues , 2017, World journal of gastroenterology.

[7]  S. Yachida,et al.  Germline mutations in Japanese familial pancreatic cancer patients , 2016, Oncotarget.

[8]  S. Gill,et al.  PANCREOX: A Randomized Phase III Study of Fluorouracil/Leucovorin With or Without Oxaliplatin for Second-Line Advanced Pancreatic Cancer in Patients Who Have Received Gemcitabine-Based Chemotherapy. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  A. Klein,et al.  Family history as a marker of platinum sensitivity in pancreatic adenocarcinoma , 2015, Cancer Chemotherapy and Pharmacology.

[10]  D. Hedley,et al.  Germline BRCA Mutations in a Large Clinic-Based Cohort of Patients With Pancreatic Adenocarcinoma. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  G. Wakabayashi,et al.  Randomised phase II trial of S-1 plus oxaliplatin vs S-1 in patients with gemcitabine-refractory pancreatic cancer , 2015, British Journal of Cancer.

[12]  J. Kench,et al.  Whole genomes redefine the mutational landscape of pancreatic cancer , 2015, Nature.

[13]  J. Furuse,et al.  Phase II study of FOLFIRINOX for chemotherapy-naïve Japanese patients with metastatic pancreatic cancer , 2014, Cancer science.

[14]  B. Dörken,et al.  Second-line oxaliplatin, folinic acid, and fluorouracil versus folinic acid and fluorouracil alone for gemcitabine-refractory pancreatic cancer: outcomes from the CONKO-003 trial. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  R. Gershoni-baruch,et al.  Overall survival and clinical characteristics of pancreatic cancer in BRCA mutation carriers , 2014, British Journal of Cancer.

[16]  Sheena M. Scroggins,et al.  Germline and Somatic Mutations in Homologous Recombination Genes Predict Platinum Response and Survival in Ovarian, Fallopian Tube, and Peritoneal Carcinomas , 2013, Clinical Cancer Research.

[17]  David Goldstein,et al.  Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. , 2013, The New England journal of medicine.

[18]  Pierre Michel,et al.  FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. , 2011, The New England journal of medicine.

[19]  R. Labianca,et al.  Randomized phase III trial of gemcitabine plus cisplatin compared with single-agent gemcitabine as first-line treatment of patients with advanced pancreatic cancer: the GIP-1 study. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  P. Catalano,et al.  Phase III, randomized study of gemcitabine and oxaliplatin versus gemcitabine (fixed-dose rate infusion) compared with gemcitabine (30-minute infusion) in patients with pancreatic carcinoma E6201: a trial of the Eastern Cooperative Oncology Group. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  K. Hess,et al.  Phase 2 trial of oxaliplatin plus capecitabine (XELOX) as second‐line therapy for patients with advanced pancreatic cancer , 2008, Cancer.

[22]  J. Furuse,et al.  A late phase II study of S-1 for metastatic pancreatic cancer , 2008, Cancer Chemotherapy and Pharmacology.

[23]  H. Ueno,et al.  Phase II study of combination chemotherapy with gemcitabine and cisplatin for patients with metastatic pancreatic cancer. , 2007, Japanese journal of clinical oncology.

[24]  H. Ueno,et al.  A multicenter phase II study of gemcitabine and S-1 combination therapy (GS therapy) in patients with metastatic pancreatic cancer , 2007 .

[25]  Osamu Ishikawa,et al.  A phase II study of weekly irinotecan as first-line therapy for patients with metastatic pancreatic cancer , 2007, Cancer Chemotherapy and Pharmacology.

[26]  H. Einsele,et al.  Randomized phase III trial of gemcitabine plus cisplatin compared with gemcitabine alone in advanced pancreatic cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  R. Labianca,et al.  Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  Alison P. Klein,et al.  Prospective Risk of Pancreatic Cancer in Familial Pancreatic Cancer Kindreds , 2004, Cancer Research.

[29]  J. Hainsworth,et al.  Randomized phase II comparison of dose-intense gemcitabine: thirty-minute infusion and fixed dose rate infusion in patients with pancreatic adenocarcinoma. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  Zhao Yu-pe.  The discussion on the issues related to NCCN clinical practice guidelines in oncology for pancreatic adenocarcinoma(V2011) , 2011 .

[31]  Wolfgang Schima,et al.  Pancreatic adenocarcinoma , 2006, European Radiology.